Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer by Abe, Akiko et al.
INTRODUCTION
Platinum-based chemotherapy is the standard
treatment for gynecologic cancers. Carboplatin has
less neurotoxicity, nephrotoxicity, gastrointestinal
toxicity, and more myelosuppression than cisplatin
and is considered therapeutically equivalent to cis-
platin in patients with ovarian cancer (1) ; therefore,
carboplatin has become a very useful agent, which
is easier to administer and can be managed even
in the outpatient clinic. All clinicians should warn
patients about myelosuppression, although it is ac-
ceptable in most cases. However, as the use of car-
boplatin has become greater, an unfavorable side ef-
fect has been noticed more frequently : hypersensi-
tivity reactions (HR), which represents a potentially
lethal complication of chemotherapy (2).
The incidence of HR with carboplatin increases
with repeated drug exposure, and is reported to oc-
cur usually from six to 21 courses of treatment (3) ;
therefore, HR is a serious problem when an ex-
tended number of courses are attempted to manage
disease recurrence. Several preventive procedures
have been proposed : premedication with antihista-
mines or corticosteroids, substitution with a differ-
ent platinum salt, and a desensitization protocol. Sev-
eral desensitization protocols using platinum agents
have been reported (2, 4-6).
Here we successfully performed a desensitization
protocol using cisplatin for three patients who de-
veloped HR to carboplatin.
PATIENTS
We retrospectively evaluated and characterized
patients with gynecologic cancers who experienced
HR associated with carboplatin administration at
our hospital from 2001 to 2007. During this period,
73 patients were treated with carboplatin-based
chemotherapy, and we identified 17 patients (22%)
with cervical (n=2), endometrial (n=4), and ovarian
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(n=11) cancer who developed a broad range of HR
attributed to carboplatin. The characteristics of the
patients are presented in Table 1. Ten patients were
treated with neoadjuvant chemotherapy and seven
with adjuvant chemotherapy. None of these patients
had an allergic response to carboplatin during the
initial treatments. HR was classified as mild or se-
vere, as reported previously (6). Reactions were con-
sidered mild if they consisted of cutaneous manifes-
tations alone, or there was no associated alteration
in pulse or blood pressure, and no evidence of bron-
chospasm. Reactions were considered severe or ana-
phylactic if symptom complexes included any altera-
tion in pulse or blood pressure. A mild allergic re-
action was recorded in 9 cases. Eight patients devel-
oped severe symptoms (Table 2). The number of
prior platinum treatments before the first HR obser-
vation varied from five to 27. All reactions occurred
during platinum infusion, and no patients developed
delayed reactions. None of the eight patients with
severe HR was rechallenged with platinum.
Three patients who had experienced mild HR
were rechallenged with carboplatin after providing
informed consent. Without desensitization, rechal-
lenge was not successful in these three patients,
who all experienced HR recurrence. The symptoms
of HR did not occur immediately after rechallenge,
but at a mean of 40 min (range 30 to 60 min) after
the initiation of infusion. Two patients developed se-
vere HR and the other mild HR. At the onset of HR,
carboplatin infusion was interrupted immediately
and patients were treated with oxygen and hydro-
cortisone. Two patients who had experienced severe
HR discontinued carboplatin chemotherapy, which
led to a poorer prognosis as this agent is the key
drug in the treatment of gynecologic cancers.
To continue platinum treatment, the other three
of 17 patients who had experienced mild HR were
treated with a desensitization protocol, substituting
cisplatin (60 mg/m2) for carboplatin (Table 3). This
regimen was performed with reference to the
Windom HH report (8). Briefly, paclitaxel (175 mg/
m2) infusion was followed by cisplatin 60 μg/m2 in
100 ml saline (1 : 1000 dilution of the final thera-
peutic dose (60 mg/m2)), 100 ml/hr1 hr, and
changed to cisplatin 600 μg/m2 in 100 ml saline (1 :
100 dilution) subsequently for 60 min. 1 : 10 dilution
infusion (cisplatin 6000 μg/m2 in 100 ml saline) was
administrated subsequently for 60 min, and then
infusion was temporarily interrupted. On the 2nd day,
treatment was initiated by cisplatin infusion at 1 : 10
dilution (cisplatin 6000 μg/m2 in 100 ml saline) for
Table 3 Summary of the patients who underwent the desensitization protocol (N=3)
Case
No. of the prior
carboplatin (cisplatin)
courses









No of courses with
desensitisation
1 22 11800 mild 60 (90 mg/body) no reaction 2
2 20 7050 mild 60 (80 mg/body) no reaction 6
3 12 (3) 5450 (240) mild 60 (80 mg/body) no reaction 2
Table 1 Characteristics of the patients (N=17)
Median age (range) 56.5 (45-69)
Stage No of the patients
Cervical cancer IIb 2
Endometrial cancer Ic 1
IIIc 2
IV 1




Initial treatment No of the patients
Neoadjuvant chemotherapy 10
Surgery-adjuvant chemotherapy 7
Initial agents No of the patients
Taxane/platinum 17
Courses of carboplatin 5-27
Cumulative dose of carboplatin 3600-12750
Table 2 Characteristics of carboplatin hypersensitivity reac-
tions (N=17)
Symptoms Number of patients
Mild erythema, pruritus 17
Nausea 3
Severe decrease in blood pressure 6
Tachycardia 2
Chest pain, bronchospasms 5
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60 min, and the remainder of the cisplatin at the
therapeutic dose was infused over eight hours.
Patients were premedicated with 50 mg pro-
methazine, 20 mg dexamethasone and 50 mg rani-




The patient was a 57-year-old woman diagnosed
with FIGO stage IIIc ovarian cancer of endometrioid
adenocarcinoma. She was treated with neoadjuvant
chemotherapy, TC (paclitaxel and carboplatin) ther-
apy for three courses, followed by debulking sur-
gery. After the operation, she received adjuvant TC
therapy for 16 courses. In the sixteenth course,
sniffles and chest pain developed during paclitaxel
administration. Mild HR to paclitaxel was consid-
ered and adjuvant chemotherapy was temporarily
interrupted. Three months later she developed re-
currence, diagnosed as a pelvic mass, and DC (do-
cetaxel and carboplatin) therapy was started. In
the third course of DC therapy (cumulative dose
of carboplatin was 11800 mg), she had mild HR
(erythema and chest pain) during carboplatin infu-
sion and infusion was stopped. Carboplatin was dis-
continued and DP therapy (docetaxel and cisplatin)
with the desensitization protocol was performed.
She received the full therapeutic dose of cisplatin
successfully without developing HR for 2 courses ;
however, further treatment was discontinued be-
cause of disease progression.
Case 2.
The patient was a 62-year-old woman diagnosed
with FIGO stage IV endometrial cancer with multi-
ple lung metastases. She was treated with debulk-
ing surgery followed by adjuvant chemotherapy (DC
therapy). In the twentieth course (cumulative dose
of carboplatin was 7050 mg), sniffles and erythema
developed during carboplatin infusion and mild HR
to carboplatin was diagnosed. Therapy included im-
mediate discontinuation of the infusion and admini-
stration of a combination of antihistamines and ster-
oids. Carboplatin was discontinued and single-agent
chemotherapy with docetaxel was given for three
additional courses. After the third course, chest CT
revealed possible drug-induced interstitial pneu-
monitis although the lung metastatic lesion was
clearly reduced. These findings led us to discontinue
further treatment.
After two-year observation without treatment, the
metastatic lesions in the lung began to spread. Af-
ter obtaining informed consent with regard to the
risk for progression of interstitial pneumonia and
critical anaphylaxis, TP therapy with the desensitiza-
tion protocol was started. This therapy was success-
fully carried out for six courses without developing
HR. Fortunately, interstitial pneumonitis did not
occur and the lung metastatic lesion disappeared.
Currently, she has in sustained remission.
Case 3.
The patient was a 52-year-old woman diagnosed
with FIGO stage IIIc serous epithelial ovarian can-
cer. She initially had a huge pelvic tumor and pre-
sented with peritonitis carcinomatosa. She was
treated with neoadjuvant chemotherapy (TC ther-
apy) for two courses followed by debulking surgery.
After the operation she received adjuvant chemo-
therapy (TC therapy) for six courses which resulted
in sustained remission. Nineteen months later, the
serum CA125 level began to elevate and multiple re-
current tumors in the intraperitoneal cavity caused
small intestinal ileus. She then underwent surgical
small intestinal bypass. After this operation, TC ther-
apy was restarted because of its high sensitivity at
initial therapy. In the third course she developed
erythema and pruritus during carboplatin infusion.
Mild HR was diagnosed and the carboplatin infusion
rate was reduced. In the next course (cumulative
dose of carboplatin of 5450 mg), rechallenge was
carried out, but mild HR occurred again. For the ad-
ditional treatments, carboplatin was discontinued
and single-agent chemotherapy with paclitaxel was
administered ; however, the serum CA125 level ele-
vated again after several courses and treatment was
replaced by a gemcitabine plus docetaxel regimen.
This therapy failed to suppress disease progression.
As she seemed to be platinum sensitive, TP therapy
was challenged in the following courses after obtain-
ing informed consent with regard to the risk for criti-
cal anaphylaxis. She was able to receive TP therapy
for two courses without developing HR. In the third
course (cumulative dose of cisplatin was 240 mg)
she had mild HR (pruritus). Although the potential
risk of critical HR was strongly considered, we de-
cided to perform TP therapy with the desensitization
protocol after obtaining her agreement. TP therapy
with desensitization was successfully carried out for
two courses without developing HR. In the third
course, she was accidently treated with TP therapy
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without the desensitization protocol. Serious HR
(tachycardia, wheezing, and decreased oxygen satu-
ration) occurred during cisplatin infusion at full
therapeutic concentration, and she was rescued with
immediate hydrocortisone and epinephrine injection.
She seemed to be sensitized to cisplatin completely
and TP therapy was discontinued. She is currently
receiving palliative care.
DISCUSSION
Carboplatin is very useful for gynecologic cancers
which had responded to prior platinum-based che-
motherapy and relapsed after more than six-month
progression-free survival (PFS). In those cases, an
extended number of courses are performed and the
cumulative dose of carboplatin is likely to be higher ;
however, the prolonged use of carboplatin increases
the incidence of HR. Markman, et al. reported that
HR was seen in 27% of patients who had received
more than seven courses of this drug therapy. The
median number of courses of carboplatin before ob-
servation of the first HR was eight. In particular, car-
boplatin treatment beyond 15 cycles and/or 8000
mg increased the risk of severe HR (7).
The severity of the symptoms varied. Occa-
sionally, HR is recognized as a subtle itching or
erythema, and in most cases (54%) more severe re-
actions, including anaphylaxis, are observed (3).
Once HR is established, rechallenge should not be
attempted because approximately 50% of cases will
experience anaphylaxis. Case 3 was rechallenged
with carboplatin after mild HR. Fortunately, she did
not develop anaphylaxis but mild HR. Zanotti, et al.
reported that the skin test is useful for identifying
patients for whom the risk of reappearance of an
allergic reaction is low (8-10).
Once patients have developed HR, they are forced
to discontinue carboplatin treatment, resulting in a
poorer prognosis because carboplatin is the key
drug for the treatment of gynecologic cancer. Thus,
it is important to suppress HR development for ex-
tended courses of carboplatin treatment.
The mechanism of HR to carboplatin remains un-
clear. It has been suggested that multiple use of this
drug is involved in the development of allergy (2,
3, 11). Repeated administration of platinum may
serve as a hapten and bind to proteins to form com-
plexes, which act as allergens. This can be classi-
fied as type 1 IgE-mediated allergy. Castells, et al.
reported that carboplatin skin testing was a helpful
predictor of reactivity (12). Several attempts have
been made to prevent HR by suppressing type 1 al-
lergy (e.g., premedication with histamine or corti-
costeroid, treatment with carboplatin at lower con-
centrations). Switch carboplatin to an alternative
platinum agent is another good option (10, 11, 13).
Cisplatin is comparable to carboplatin in terms of
anti-tumor activity in gynecologic cancers. Although
cross-reactivity between carboplatin and cisplatin
should be considered, antigenicity may differ be-
tween these two platinum preparations. Occasion-
ally, the absence of HR to cisplatin is reported in
patients who have experienced HR to carboplatin
in previous treatment. Callahan, et al. reported that
among patients who have developed HR to car-
boplatin in initial treatment, only 8% were unable to
complete cisplatin therapy without prior desensiti-
zation (6) ; therefore, substituting cisplatin for car-
boplatin after HR development is a good strategy if
continuation of platinum-based chemotherapy is
highly desirable.
Another method for preventing HR to carboplatin
is a desensitization protocol by gradual re-introduc-
tion of small amounts of drug antigens to full thera-
peutic doses (2, 4). In our three patients, all had
undergone many more than seven courses of car-
boplatin chemotherapy ; therefore, further treat-
ments with platinum were much more likely to re-
sult in HR. Thus, we attempted a desensitization
protocol by replacing carboplatin with cisplatin with
eight-hour prolonged infusion at a therapeutic dose.
This protocol was successful in all three patients, ex-
cept for one treatment course. Generally, alteration
of the successful protocol (e.g. to render them faster
or to significantly change the time interval between
doses) should be avoided. In the one failed treat-
ment course, the desensitization protocol was erro-
neously skipped and the patient rapidly developed
anaphylaxis just after the initiation of cisplatin infu-
sion at the full therapeutic dose, although she had
undergone successful desensitization protocols until
the previous treatment. This result supports the use-
fulness of our approach to HR prevention.
However, further continuation of cisplatin treat-
ment with our desensitization protocol is barely suc-
cessful for suppressing HR (5). Jones, et al. reported
the outcome of five patients treated for ovarian can-
cer with cisplatin after HR to carboplatin. Three of
five patients were successfully re-treated, but one
patients once again developed HR during the second
cycle. The other patient developed recurrent symp-
toms during the 4th cycle. Further investigations
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are needed to define the cellular and molecular
mechanisms underlying desensitization. One pos-
sible method may be to switch cisplatin for another
platinum treatment (e.g. oxalliplatin or nedaplatin)
while the desensitization protocol shows potential
to continue platinum-based chemotherapy. Another
method may be to switch intravenous infusion to
intraperitoneal administration (IP). Fujiwara, et al.
reported that IP therapy with low toxicity might re-
duce the risk of HR (14).
We reported the usefulness and effectiveness of
the desensitization protocol for the continuation of
platinum treatment in patients who had undergone
an extended number of carboplatin treatments. It
is important to state that the aim of this report is
not to negate the potential utility of carboplatin in
patients with ovarian cancer who have experienced
an allergic reaction to the agent.
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